Hopes were high for tipifarnib a few years ago, when Kura Oncology Inc., of La Jolla, Calif., completed a reverse merger and closed a $60 million private placement with a syndicate of top venture funds around the same time it executed an agreement with Johnson & Johnson (J&J) unit Janssen Pharmaceutica NV, of Beerse, Belgium, for an exclusive license to develop and commercialize the oral farnesyltransferase inhibitor in multiple oncology indications. Read More
